Reports Q3 revenue $12.50M, consensus $11.2M. “This has been a historic period for Syndax (SNDX) as we transitioned to a commercial-stage company with the approval of Niktimvo. With the recently completed royalty financing, we expect to be funded through profitability and we are well positioned to maximize the potential of our pipeline,” said Michael A. Metzger, CEO. “We have a very exciting quarter ahead with the anticipated FDA approval and U.S. launch of revumenib for adults and pediatrics with R/R KMT2Ar acute leukemia, as well as the expected readout of topline pivotal data from patients with R/R mNPM1 AML. Our commercial organization is well-prepared to launch revumenib and leverage our first-to-market position to drive long-term value creation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNDX:
- Syndax to present new data on revumenib in leukemia
- Royalty Pharma enters $350M synthetic royalty funding agreement with Syndax
- Syndax, Royalty Pharma enter $350M royalty funding agreement for Niktimvo
- SNDX Upcoming Earnings Report: What to Expect?
- Verizon downgraded, Canadian Pacific upgraded: Wall Street’s top analyst calls